Skip to main content
Links to homepage of ULTOMIRIS patient site

Call us at 1-877-GMG-ULTO (877-464-8586)

About gMG

What is gMG?

Generalized myasthenia gravis (gMG) is a rare autoimmune disease that impacts the neuromuscular system

It is estimated that more than 71,000 people in the United States are living with anti-acetylcholine receptor (AChR) antibody-positive gMG.

Despite available treatments, 50% of the people in a study reported still experiencing gMG symptoms that limited their everyday life.

71,000 gMG patients in the United States

Despite available treatments, 50% of the people in a study reported still experiencing gMG symptoms that limited their everyday life.

In gMG, a part of your immune system called complement disrupts signals between your muscles and nerves

Normally, the complement system helps your body fight off infections. But when you have gMG, complement causes worsening damage to the neuromuscular junction, the area where the nerves and muscles meet.

How can gMG damage muscles?

Explore ULTOMIRIS in the Body

Step 1:

Anti-AChR antibodies block your muscle receptors. Your body identifies this as a threat and responds by activating the complement system.

Step 2:

The complement system, activated in part by a key protein called C5, contributes to damage on the surface of your muscles.

Step 3:

Muscle cell damage prevents your receptors from receiving nerve signals, causing the gMG symptoms you may experience.

Muscle damage caused by gMG can make daily activities and physical functions challenging

Vision

For many patients, double vision and drooping eyelids are the first symptoms of gMG. Vision problems may impact your ability to drive, read, or watch TV.

Breathing

When gMG damages the muscles of your diaphragm, you may experience trouble breathing. Breathing impairment may impact your ability to speak or move around.

Speech

gMG can make it hard to speak or may cause you to slur your words. Speech difficulties may make it tough for those around you to understand what you are saying.

Eating

Muscle weakness associated with gMG can make it harder to swallow or hold your head up. Eating difficulties may impact your ability to go out to eat or even eat alone.

Mobility

Since gMG damages your muscles, you may experience weakness in your arms and/or legs. Muscle weakness can make personal grooming, household chores, and traveling more difficult to do.

Use this questionnaire to assess your gMG symptoms. Then, talk to your doctor about your results

Download the gMG symptom questionnaire

Receive information & updates

Stay Connected

IMPORTANT SAFETY INFORMATION INCLUDING BOXED WARNING

What is the most important information I should know about ULTOMIRIS?
ULTOMIRIS is a medicine that affects your immune system and can lower the ability of your immune system to fight infections.

  • ULTOMIRIS increases your chance of getting serious and life-threatening meningococcal infections that may quickly become life-threatening and cause death if not recognized and treated early.
  1. You must receive meningococcal vaccines at least 2 weeks before your first dose of ULTOMIRIS if you are not vaccinated.
  2. If your healthcare provider decided that urgent treatment with ULTOMIRIS is needed, you should receive meningococcal vaccination as soon as possible.
  3. If you have not been vaccinated and ULTOMIRIS therapy must be initiated immediately, you should also receive 2 weeks of antibiotics with your vaccinations.
  4. If you had a meningococcal vaccine in the past, you might need additional vaccination. Your healthcare provider will decide if you need additional vaccination.
  5. Meningococcal vaccines reduce but do not prevent all meningococcal infections. Call your healthcare provider or get emergency medical care right away if you get any of these signs and symptoms of a meningococcal infection: headache with nausea or vomiting, headache and fever, headache with a stiff neck or stiff back, fever, fever and a rash, confusion, muscle aches with flu-like symptoms and eyes sensitive to light.

Your healthcare provider will give you a Patient Safety Card about the risk of meningococcal infection. Carry it with you at all times during treatment and for 8 months after your last ULTOMIRIS dose. It is important to show this card to any healthcare provider or nurse to help them diagnose and treat you quickly.

ULTOMIRIS is only available through a program called the ULTOMIRIS REMS. Before you can receive ULTOMIRIS, your healthcare provider must: enroll in the ULTOMIRIS REMS program; counsel you about the risk of meningococcal infection; give you information and a Patient Safety Card about the symptoms and your risk of meningococcal infection (as discussed above); and make sure that you are vaccinated with a meningococcal vaccine, and if needed, get revaccinated with the meningococcal vaccine. Ask your healthcare provider if you are not sure if you need to be revaccinated.

ULTOMIRIS may also increase the risk of other types of serious infections. Call your healthcare provider right away if you have any new signs or symptoms of infection.

Who should not receive ULTOMIRIS?
Do not receive ULTOMIRIS if you have a meningococcal infection or have not been vaccinated against meningococcal infection unless your healthcare provider decides that urgent treatment with ULTOMIRIS is needed.

Before you receive ULTOMIRIS, tell your healthcare provider about all of your medical conditions, including if you: have an infection or fever, are pregnant or plan to become pregnant, and are breastfeeding or plan to breastfeed. It is not known if ULTOMIRIS will harm your unborn baby or if it passes into your breast milk. You should not breastfeed during treatment and for 8 months after your final dose of ULTOMIRIS.

Tell your healthcare provider about all the vaccines you receive and medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements which could affect your treatment.

What are the possible side effects of ULTOMIRIS?
ULTOMIRIS can cause serious side effects including infusion-related reactions. Symptoms of an infusion-related reaction with ULTOMIRIS may include lower back pain, tiredness, feeling faint, discomfort in your arms or legs, bad taste, or drowsiness. Stop treatment of ULTOMIRIS and tell your healthcare provider or nurse right away if you develop these symptoms, or any other symptoms during your ULTOMIRIS infusion that may mean you are having a serious infusion reaction, including: chest pain, trouble breathing or shortness of breath, swelling of your face, tongue, or throat, and feel faint or pass out.

The most common side effects of ULTOMIRIS in people with gMG are diarrhea and upper respiratory tract infections.

Tell your healthcare provider about any side effect that bothers you or that does not go away. These are not all the possible side effects of ULTOMIRIS. For more information, ask your healthcare provider or pharmacist. Call your healthcare provider right away if you miss an ULTOMIRIS infusion or for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

INDICATION
What is ULTOMIRIS?
ULTOMIRIS is a prescription medicine used to treat adults with a disease called generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.

It is not known if ULTOMIRIS is safe and effective for the treatment of gMG in children.

Please see the full Prescribing Information and Medication Guide for ULTOMIRIS, including Boxed WARNING regarding serious and life-threatening meningococcal infections/sepsis.

Questions? Call us at 1-877-GMG-ULTO (877-464-8586)